Atlas chapter 14 · Fatigue / wellbeing

Reishi / Lingzhi

Ganoderma spp.

E2-3 ± (proposition-specific)± — Materially mixedR1 — one controlled clinical programme was identified for the grade-owning Ganopoly fatigue/wellbeing proposition in neurasthenia (Tang et al., J Med Food 2005;8(1):53–58; PMID 15857210). Controlled Ganoderma studies in other populations and indications (Klupp 2016; Chu 2012) provide important context for the heterogeneous evidence landscape but do not constitute independent replication of this proposition. Secondary syntheses, preparation-identity studies, taxonomic studies and safety reports are not counted as replications. R1 describes replication depth, not trial quality or effect direction.

Proposition / claim: A defined Ganoderma polysaccharide extract (Ganopoly) produced a controlled positive signal for fatigue and wellbeing in a neurasthenia population.
Evidence owner: The defined Ganoderma polysaccharide preparation Ganopoly used in the controlled neurasthenia trial; the positive fatigue/wellbeing signal belongs to that preparation, population and outcome, not to Reishi/Ganoderma as a single organism-wide medicine. The trial's source material was reported as Ganoderma lucidum and no modern species authentication is implied.
Dominant uncertainty: Biological identity and preparation identity underlying a heterogeneous clinical literature.

Organism: Ganoderma spp.
Tested intervention: Ganopoly — a defined Ganoderma polysaccharide extract used in the controlled neurasthenia trial. The original study reported the source material as Ganoderma lucidum; that historical identification is preserved as reported and is not restated as authenticated Ganoderma lingzhi.
Evidence target: Standardized preparation
Intervention description: A defined Ganoderma polysaccharide preparation (Ganopoly) administered for eight weeks in the controlled neurasthenia trial. The evidence belongs to that preparation, the dose and exposure represented in the trial, the population studied and the outcomes measured. It does not extend to whole Reishi mushroom, fruiting-body powder, spore powder, spore oil, ethanol extracts, arbitrary extracts or generic commercial Reishi supplements.
Population: 132 people diagnosed with neurasthenia.
Comparator: Placebo. The trial was randomized, double-blind and placebo-controlled.
Outcome: Fatigue and wellbeing measures after eight weeks; the active-treatment group improved more than placebo. These endpoints are fatigue and wellbeing measures only and are not general vitality, longevity, immune function or metabolic health.
Evidence maturity (E): E2-3 ± (proposition-specific)
Direction: ± — Materially mixed
Historical flag (H): Not specified at dossier level
Replication (R): R1 — one controlled clinical programme was identified for the grade-owning Ganopoly fatigue/wellbeing proposition in neurasthenia (Tang et al., J Med Food 2005;8(1):53–58; PMID 15857210). Controlled Ganoderma studies in other populations and indications (Klupp 2016; Chu 2012) provide important context for the heterogeneous evidence landscape but do not constitute independent replication of this proposition. Secondary syntheses, preparation-identity studies, taxonomic studies and safety reports are not counted as replications. R1 describes replication depth, not trial quality or effect direction.
Claim Gap (CG): CG0 — A randomized placebo-controlled trial found improved fatigue and wellbeing scores from a defined Ganoderma polysaccharide preparation in people with neurasthenia. CG1 — Some controlled human evidence suggests that certain Ganoderma preparations may improve fatigue in particular populations. CG2-3 — Reishi improves energy. CG3-4 — Reishi balances blood sugar and cholesterol. CG4 — Reishi is scientifically proven to support immunity, metabolism and longevity. Claim ceiling: CG1-2 for preparation-specific controlled findings. Controlled cardiometabolic trials do not support the broader rungs: a 2016 double-blind randomized placebo-controlled trial in 84 adults with type 2 diabetes and metabolic syndrome found no significant improvement in principal cardiovascular-risk outcomes including glycaemic measures, blood pressure, weight or serum lipids, and an earlier controlled crossover study likewise found no broad improvement in body weight, blood pressure, fasting glucose or lipids, with exploratory signals and carry-over limitations. Those trials test different propositions; they neither cancel nor support the neurasthenia finding. A medicinal name is not a proposition.
Evidence Transfer Vector: Transferred proposition: "Reishi supplements improve metabolic health." Vectors crossed: T / I / O / R / D. T — Taxon: historical "Ganoderma lucidum" → whatever Ganoderma species is present in the current product. I — Intervention: specific clinical preparation → generic supplement. O — Outcome: individual metabolic measurements → broad "metabolic health". R — Replication: limited and mixed clinical programmes → established effect. D — Dose: clinical preparation and exposure → commercial dose.
Taxonomic Transfer Confidence: LOW-VARIABLE historically. Historical East Asian "G. lucidum" → modern G. lucidum sensu stricto: LOW unless authenticated or preserved for reassessment. Historical East Asian "G. lucidum" → G. lingzhi: plausible in many contexts, but case-specific and not automatically proven. Authenticated G. lingzhi → another authenticated G. lingzhi preparation: taxonomically stronger, but intervention equivalence still requires separate evidence.
Intervention Transfer Confidence: LOW-VARIABLE across preparations. The same Ganoderma species can yield polysaccharide extracts, spore powders, spore oils, fruiting-body powders, ethanol extracts and other formulations. Same species does not mean same intervention.
Safety: S2 — short controlled studies generally report favourable tolerability and substantial human exposure exists, but this does not mean universal safety. Rare clinically apparent liver injury has been reported in association with Reishi/Lingzhi products; causality and product attribution can be uncertain, and the event appears very uncommon relative to worldwide exposure. Powders, extracts, spores, oils and multi-ingredient products may differ.
Conservation: C0/C+ — cultivation can reduce dependence on wild harvest and improve authenticated strain deposition, standardization, batch archiving and chemical characterization.
Resolution zone: RZ-5 → RZ-2/3 — first authenticate and characterize the biological material and preparation, then perform proposition-specific confirmatory work rather than collapsing immediately to a large clinical trial.
Next best experiment: Establish intervention identity first: molecularly authenticated fungal material, recorded strain provenance, standardized cultivation, defined tissue, standardized extraction, defined dose, documented manufacturing, archived batches and chemical characterization. Then select one clinically meaningful proposition and test it. Before expensive species-versus-species clinical testing, analytical and metabolomic comparison may be the more efficient identity-resolution step. Authenticate and characterize first; then perform proposition-specific confirmatory clinical testing.
Primary references: GRADE-OWNING / PRIMARY — Tang W, Gao Y, Chen G, Gao H, Li X, Ye S, Cao Y, Zhou S. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food. 2005 Spring;8(1):53-58. doi:10.1089/jmf.2005.8.53. PMID 15857210. Randomized, double-blind, placebo-controlled trial in 132 patients diagnosed with neurasthenia; intervention was Ganopoly, a defined Ganoderma polysaccharide extract, taken for eight weeks; comparator placebo. Fatigue and wellbeing measures improved more in the treated group than in placebo. This reference alone owns the grade for the narrow fatigue/wellbeing proposition. The fungal source is reported by the authors as Ganoderma lucidum; that historical identification is preserved as reported and is not restated as authenticated Ganoderma lingzhi. Limitations: single controlled programme, single-country investigator group, subjective symptom endpoints, no modern species authentication of the source material. Counts as one controlled programme for replication; owns no claim beyond Ganopoly, neurasthenia and fatigue/wellbeing.
CONTROLLED CONTRADICTORY OR NEUTRAL EVIDENCE — Klupp NL, Kiat H, Bensoussan A, Steiner GZ, Chang DH. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep. 2016 Aug 11;6:29540. doi:10.1038/srep29540. PMID 27511742. Double-blind randomized placebo-controlled trial in 84 adults with type 2 diabetes mellitus and metabolic syndrome; tested a Ganoderma lucidum preparation (alone and with Cordyceps sinensis) against placebo. No significant benefit on the principal cardiovascular-risk outcomes, including glycaemic measures, blood pressure, body weight and serum lipids. Tests a different proposition from the neurasthenia trial: it neither cancels nor supports it. Its dossier role is to evidence proposition-specific heterogeneity and the dossier-level plus/minus direction. Does not count as replication of the fatigue/wellbeing proposition: different preparation, population, endpoints and clinical question.
CONTROLLED CONTRADICTORY OR NEUTRAL EVIDENCE — Chu TT, Benzie IF, Lam CW, Fok BS, Lee VH, Tomlinson B. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. Br J Nutr. 2012 Apr;107(7):1017-1027. doi:10.1017/S0007114511003795. PMID 21801467. Earlier controlled crossover human intervention study of a Lingzhi preparation in adults; no broad improvement in body weight, blood pressure, fasting glucose or serum lipids. Some exploratory signals were reported, and the crossover design carries recognised carry-over limitations. Preparation, population and outcome framework differ from the neurasthenia trial; provides neutral cardiometabolic context only. Non-grade-owning; does not count toward replication of the fatigue/wellbeing proposition.
SYSTEMATIC REVIEW / SECONDARY SYNTHESIS — Klupp NL, Chang D, Hawke F, Kiat H, Cao H, Grant SJ, Bensoussan A. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015 Feb 17;2015(2):CD007259. doi:10.1002/14651858.CD007259.pub2. PMID 25686270. Cochrane synthesis of controlled trials of Ganoderma lucidum for cardiovascular risk factors; found the evidence base small, heterogeneous in preparation and insufficient to support cardiometabolic benefit. Secondary synthesis only: it does not own any grade and does not count as an independent clinical replication of its constituent trials. Relevant to the claim-gap ceiling, not to the neurasthenia proposition.
PREPARATION / INTERVENTION IDENTITY — Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of Ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003 Aug;32(3):201-215. doi:10.1081/imm-120022979. PMID 12916709. Establishes the identity and clinical use of Ganopoly as a specific water-soluble Ganoderma polysaccharide extract, distinct from fruiting-body powder, mycelial products, spore powder, spore oil, ethanol extracts and generic commercial supplements. Stored for intervention identity only. Different population and outcome from the grade-owning trial; it neither owns nor increases the fatigue/wellbeing grade and is not a replication.
TAXONOMIC / IDENTITY — Cao Y, Wu SH, Dai YC. Species clarification of the prize medicinal Ganoderma mushroom "Lingzhi". Fungal Diversity. 2012;56(1):49-62. doi:10.1007/s13225-012-0178-5. Establishes that the East Asian cultivated and medicinally used "Lingzhi" is largely not Ganoderma lucidum sensu stricto (a European-typified species) and describes Ganoderma lingzhi as a separate species. Documents, rather than resolves, the identity problem: it does not retrospectively authenticate any historical clinical preparation, including the material used in the neurasthenia trial. Taxonomic continuity and intervention equivalence remain separate questions; this reference owns no clinical grade.
TAXONOMIC / IDENTITY — Hennicke F, Cheikh-Ali Z, Liebisch T, Macia-Vicente JG, Bode HB, Piepenbring M. Distinguishing commercially grown Ganoderma lucidum from Ganoderma lingzhi from Europe and East Asia on the basis of morphology, molecular phylogeny, and triterpenic acid profiles. Phytochemistry. 2016 Jul;127:29-37. doi:10.1016/j.phytochem.2016.03.012. PMID 27044336. Shows that commercially grown material sold as Ganoderma lucidum separates from Ganoderma lingzhi by morphology, molecular phylogeny and triterpenic acid profile, and that chemical profiles differ between them. Supports LOW-VARIABLE taxonomic transfer confidence and the dossier position that species label alone does not establish material identity. Does not authenticate historical clinical material and owns no clinical grade.
SAFETY SIGNAL — Yuen MF, Ip P, Ng WK, Lai CL. Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). J Hepatol. 2004 Oct;41(4):686-687. doi:10.1016/j.jhep.2004.06.016. PMID 15464254. Case report of hepatotoxicity following use of a Ganoderma lucidum (Lingzhi) formulation; the specific commercial product form is central to the report and species authentication was not performed. Supports a rare liver-injury signal with uncertain preparation-specific generalizability. Isolated case evidence: it establishes no incidence rate, no population risk estimate and no class-wide hepatotoxicity for Ganoderma preparations.
SAFETY SIGNAL — Wanmuang H, Leopairut J, Kositchaiwat C, Wananukul W, Bunyaratvej S. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai. 2007 Jan;90(1):179-181. PMID 17621752. Fatal case of fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder taken after prior uneventful use of a different Lingzhi preparation, illustrating that powder, extract and other product forms are not interchangeable for safety purposes. No species authentication; causal attribution is limited by concomitant exposures and absence of rechallenge. Supports the rare liver-injury signal only; does not establish frequency or class-wide risk.
SAFETY SIGNAL — Guedikian R, Kim B, Singh G, Alexander R, et al. Ganoderma lingzhi (Reishi mushroom)-induced acute liver injury in the setting of alcohol use: a case report and review of the literature. Cureus. 2023 Sep;15(9):e45953. doi:10.7759/cureus.45953. PMID 37885515. Contemporary case report of acute liver injury attributed to a Reishi product, with concurrent alcohol use as a confounding exposure and no independent species authentication of the consumed product. Sustains the rare liver-injury signal into the modern literature while demonstrating the attribution limits typical of this evidence: single case, confounded exposure, uncertain product identity. Not an incidence estimate and not evidence of common or class-wide hepatotoxicity.
Source chapter: Chapter 14, The Fungal Evidence Atlas